Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

6.850 +0.070 (+1.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 772,671
Open 6.820
Bid (Size) 6.150 (1)
Ask (Size) 7.890 (1)
Prev. Close 6.780
Today's Range 6.605 - 6.900
52wk Range 4.620 - 13.47
Shares Outstanding 59,762,106
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
Earnings Scheduled For April 29, 2025
Via Benzinga

Performance

YTD
+18.5%
+18.5%
1 Month
+2.1%
+2.1%
3 Month
-5.8%
-5.8%
6 Month
+23.2%
+23.2%
1 Year
-35.3%
-35.3%

More News

Read More
What to Expect from Sage Therapeutics's Earnings
Via Benzinga
Expert Outlook: Sage Therapeutics Through The Eyes Of 4 Analysts
Via Benzinga
Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025
From Sage Therapeutics, Inc.
Via Business Wire
A Glimpse Into The Expert Outlook On Sage Therapeutics Through 7 Analysts
Via Benzinga
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
From Kahn Swick & Foti, LLC
Via Business Wire
US Stocks Likely To Open Mixed: 'Expect Volatility. Buckle Up,' Says Expert
Via Benzinga
Topics Supply Chain World Trade
Exposures Supply Chain Tariff
KB Home Posts Downbeat Results, Joins UniFirst, Oklo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Why Power Solutions International Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Notice to Long-Term Shareholders of Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Is Investigating Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE
From Kahn Swick & Foti, LLC
Via Business Wire
Notice to Long-Term Shareholders of Mercury Systems, Inc. (NASDAQ: MRCY); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your
From Grabar Law Office
Via GlobeNewswire
Long-Term Shareholder Notice: Fluence Energy, Inc. (NASDAQ: FLNC); Kyverna Therapuetics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Long-Term Shareholder Notice: Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf
From Grabar Law Office
Via GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as
From Grabar Law Office
Via GlobeNewswire
Sage Therapeutics Announces R&D Leadership Transition
From Sage Therapeutics, Inc.
Via Business Wire
Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates
From Sage Therapeutics, Inc.
Via Business Wire
What To Expect From Alzheimer's Drugmaker Biogen's Q4 Earnings On Wednesday?
Via Benzinga
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok
Via Benzinga
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
From Sage Therapeutics, Inc.
Via Business Wire
Biogen Rises On FDA Nod for Alzheimer's Drug Dosing Regimen, But Sage Deal Fallout Irks Retail
Via Stocktwits
Exposures Product Safety
Earnings Scheduled For February 11, 2025
Via Benzinga
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal
From Sage Therapeutics, Inc.
Via Business Wire
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Via Benzinga
Topics Government
Exposures Political

Frequently Asked Questions

Is Sage Therapeutics, Inc. - Common Stock publicly traded?
Yes, Sage Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Sage Therapeutics, Inc. - Common Stock trade on?
Sage Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sage Therapeutics, Inc. - Common Stock?
The ticker symbol for Sage Therapeutics, Inc. - Common Stock is SAGE on the Nasdaq Stock Market
What is the current price of Sage Therapeutics, Inc. - Common Stock?
The current price of Sage Therapeutics, Inc. - Common Stock is 6.850
When was Sage Therapeutics, Inc. - Common Stock last traded?
The last trade of Sage Therapeutics, Inc. - Common Stock was at 06/06/25 04:00 PM ET
What is the market capitalization of Sage Therapeutics, Inc. - Common Stock?
The market capitalization of Sage Therapeutics, Inc. - Common Stock is 409.37M
How many shares of Sage Therapeutics, Inc. - Common Stock are outstanding?
Sage Therapeutics, Inc. - Common Stock has 409M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.